Literature DB >> 1963796

Selective chiral inhibitors of 5-lipoxygenase with anti-inflammatory activity.

R M McMillan1, J M Girodeau, S J Foster.   

Abstract

The studies described here, using enantiomers of an optically-active methoxy alkyl thiazole ICI216800 (1-methoxy-6-(naphth-2-yl-methoxyl)-1- (thiazol-2-yl)indane), provide unequivocal evidence for a specific, chiral interaction with 5-lipoxygenase. In accordance with their biochemical efficacy these compounds also demonstrate enantio-specific anti-inflammatory activity in a leukotriene-mediated model of inflammation. This is the first class of compounds for which 5-lipoxygenase inhibition and anti-inflammatory activity have been shown to be mediated via a specific chiral interaction.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1963796      PMCID: PMC1917719          DOI: 10.1111/j.1476-5381.1990.tb14111.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  5 in total

1.  Leukotriene B4 and prostaglandin E2 mediate the inflammatory response of rabbit skin to intradermal arachidonic acid.

Authors:  D M Aked; S J Foster
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

2.  Kinetic mechanism of guinea pig neutrophil 5-lipoxygenase.

Authors:  D Aharony; R L Stein
Journal:  J Biol Chem       Date:  1986-09-05       Impact factor: 5.157

3.  2-substituted indazolinones: orally active and selective 5-lipoxygenase inhibitors with anti-inflammatory activity.

Authors:  S J Foster; P Bruneau; E R Walker; R M McMillan
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

4.  Relationship between inhibition of prostaglandin synthesis and drug efficacy: support for the current theory on mode of action of aspirin-like drugs.

Authors:  R V Tomlinson; H J Ringold
Journal:  Biochem Biophys Res Commun       Date:  1972-01-31       Impact factor: 3.575

5.  Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo.

Authors:  J E Tateson; R W Randall; C H Reynolds; W P Jackson; P Bhattacherjee; J A Salmon; L G Garland
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

  5 in total
  7 in total

Review 1.  Pharmacological inhibition of leukotriene actions.

Authors:  F Engels; F P Nijkamp
Journal:  Pharm World Sci       Date:  1998-04

2.  Specific inhibition of leukotriene B4 (LTB4)-induced neutrophil emigration by 20-hydroxy LTB4: implications for the regulation of inflammatory responses.

Authors:  E R Pettipher; E D Salter; R Breslow; L Raycroft; H J Showell
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

3.  Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.

Authors:  R M McMillan; K E Spruce; G C Crawley; E R Walker; S J Foster
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

4.  Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses.

Authors:  S M Nasser; G S Bell; R J Hawksworth; K E Spruce; R MacMillan; A J Williams; T H Lee; J P Arm
Journal:  Thorax       Date:  1994-08       Impact factor: 9.139

5.  Methoxyalkyl thiazoles: a novel series of potent, orally active and enantioselective inhibitors of 5-lipoxygenase.

Authors:  R M McMillan; T G Bird; G C Crawley; M P Edwards; J M Girodeau; J F Kingston; S J Foster
Journal:  Agents Actions       Date:  1991-09

6.  Lipoxygenase inhibitory activity of U-66,858 and its deacetylated metabolite U-68,244 in human whole blood.

Authors:  J A Summers; A Bye; C Robinson
Journal:  Agents Actions       Date:  1994-03

7.  Design and Synthesis of New Benzophenone Derivatives with In Vivo Anti-Inflammatory Activity through Dual Inhibition of Edema and Neutrophil Recruitment.

Authors:  Jaqueline P Januario; Thiago B de Souza; Stefânia N Lavorato; Tatiane C S Maiolini; Olívia S Domingos; João L Baldim; Laís R S Folquitto; Marisi G Soares; Daniela A Chagas-Paula; Danielle F Dias; Marcelo H Dos Santos
Journal:  Molecules       Date:  2018-07-26       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.